PQA Home PQA Home Phone (703) 347-7963
Contact Us Online
"Optimizing Health by Advancing the Quality of Medication Use"
HOME ABOUT PQA ACADEMIC MEASURES MEMBERSHIP MDTs and SAPs RESOURCES
 
PQA Measures


PQA Newsletter



 
Pharmacy Quality Alliance

5911 Kingstowne Village Parkway, Suite 130
Alexandria, Virginia   22315

Phone: (703) 347-7963


To contact us, email:
info@pqaalliance.org
or click here.


PQA Performance Measures


 

PQA Measure Development
PQA uses a systematic, transparent, consensus-based process to draft, test, refine, and endorse high-priority measures of medication-use. View the PQA process for developing and testing performance measures.


PQA Member Voting
Guidance for PQA member organizations participating in the voting process is available here.  The guidance document provides a comprehensive overview of the PQA measure endorsement voting process including details for member organizations to prepare for a vote, know who can participate in the voting, how to cast a vote, and when it is appropriate to abstain from a measure endorsement vote.


PQA Measure Manual and National Drug Code (NDC) Lists
PQA owns and maintains the performance measures and quality improvement indicators listed within the PQA Measure Manual.  NDC lists, which are required to accurately calculate each measure, are updated twice annually. The PQA Measure Manual includes all measure specifications and is provided upon request to PQA members for non-commercial purposes. 

The licensing section of the PQA web site provides additional information for organizations interested in using the PQA measures as part of a commercial product and for non-members to request individual measure specifications for quality improvement purposes.


PQA Performance Measures
The following endorsed measures are reviewed regularly by the PQA Measure Update Panel and are updated as needed. Download an overview of PQA-endorsed measures.

Adherence

  • Proportion of Days Covered: Diabetes All Class (PDC-DR) (NQF #0541)
  • Proportion of Days Covered: Renin Angiotensin System Antagonists (PDC-RASA) (NQF #0541)
  • Proportion of Days Covered: Statins (PDC-STA) (NQF #0541)
  • Proportion of Days Covered: Beta-blockers (PDC-BB)
  • Proportion of Days Covered: Calcium Channel Blockers (PDC-CCB)
  • Proportion of Days Covered: Biguanides (PDC-BG)
  • Proportion of Days Covered: Dipeptidyl Peptidase (DPP)-4 Inhibitors (PDC-DPP)
  • Proportion of Days Covered: Sulfonylureas (PDC-SFU)
  • Proportion of Days Covered: Thiazolidinediones (PDC-TZD)
  • Adherence to Non-Warfarin Oral Anticoagulants (PDC-NOAC)
  • Adherence to Long-Acting Inhaled Bronchodilator Agents in COPD (PDC-COPD)
  • Proportion of Days Covered: Antiretrovirals (PDC-ARV)
  • Non-infused Disease Modifying Agents used to Treat Multiple Sclerosis (MS) (PDC-MS)
  • Treatment of Chronic Hepatitis C: Completion of Therapy (HCV)
  • Primary Medication Nonadherence (PMN)
  • Adherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA) - PQA endorsed, May 2018


Appropriate Medication Use

  • Diabetes Medication Dosing (DOS)
  • Statin Use in Persons with Diabetes (SUPD) (NQF #2712)
  • Medication Therapy for Persons with Asthma (MTPA)


Medication Safety

  • Drug-Drug Interactions (2017 Update) (DDI-2017)
  • Antipsychotic Use in Persons with Dementia (APD) (NQF #2111)
  • Antipsychotic Use in Persons with Dementia: MDS (APD-MDS)
  • Antipsychotic Use in Children under 5 Years (APC) (NQF #2337)
  • Use of High-Risk Medications in the Elderly (2017 Update) (HRM-2017)
  • Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly (BSH)
  • Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults (POLY-ACH)
  • Polypharmacy: Use of Multiple CNS-Active Medications in Older Adults (POLY-CNS)
  • Concurrent Use of Opioids and Benzodiazepines (COB)
  • Use of Opioids at High Dosage in Persons Without Cancer (OHD) (NQF #2940)
  • Use of Opioids from Multiple Providers in Persons Without Cancer (OMP) (NQF #2950)
  • Use of Opioids at High Dosage and from Multiple Providers in Persons Without Cancer (OHDMP) (NQF #2951)


Medication Therapy Management

  • Completion Rate for Comprehensive Medication Review (CMR)

PQA Quality Improvement Indicators
To request PQA-approved Quality Improvement Indicators (QIIs), click here.


For information on:

  • measure development and voting, contact Lynn Pezzullo at LPezzullo@PQAalliance.org.
  • licensing PQA measures, contact Jackie Green at JGreen@PQAalliance.org.
  • measure specification and NDC list requests, contact Lisa Hines at LHines@PQAalliance.org.



 
© Copyright 2018 Pharmacy Quality Alliance | Site Development & Hosting By ISADEX Corporation | Terms | Privacy Visit Us On Facebook      Visit Us On Twitter      Visit Us On LinkedIn